Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Alexza Pharmaceuticals received early financing of $19.7M on 2009-10-06.
| Series | Round size | Date |
|---|---|---|
| Equity | $5M | 02/2016 |
| Equity | $144K | 09/2015 |
| Equity | $8M | 10/2014 |
| Debt | $25M | 05/2013 |
| Equity | $3M | 03/2012 |
| Options | $1M | 05/2010 |
| Equity | $19.7M | 10/2009 |
| Investors | Security type |
|---|---|
| 5AM Ventures | Series D - Alexza Pharmaceuticals |
| CMEA Ventures | Series D - Alexza Pharmaceuticals |
| Alloy Ventures | Series D - Alexza Pharmaceuticals |
| Delphi Ventures | Series D - Alexza Pharmaceuticals |
| New Enterprise Associates (NEA) | Series D - Alexza Pharmaceuticals |
| MDS Capital | Series D - Alexza Pharmaceuticals |
| Versant Ventures | Series D - Alexza Pharmaceuticals |
| Burrill & Company | Series D - Alexza Pharmaceuticals |
| Frazier Healthcare Partners | Series D - Alexza Pharmaceuticals |
| Pacific Rim Ventures | Series D - Alexza Pharmaceuticals |
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Cytovance Biologics | $73,328 | $12.0M | 261 | 5 |
| Nektar Therapeutics | $83,561 | $98.4M | 718 | - |
| Argos Therapeutics | $72,478 | $1.9M | 76 | - |
| Acusphere | $76,389 | - | 118 | - |
| Hemispherx Biopharma, Inc. | $70,511 | $335,000 | 33 | - |
| Actavis Laboratories FL, Inc. | $68,450 | $162.9M | 900 | - |
| Avrio Biopharmaceuticals | $73,019 | $3.2M | 125 | - |
| AGC Biologics | $66,596 | $9.8M | 2,151 | 6 |
| LSNE Contract Manufacturing | $67,391 | $9.2M | 15 | - |
| G&W Laboratories | $67,065 | $527.2M | 300 | - |
Zippia gives an in-depth look into the details of Alexza Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alexza Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Alexza Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alexza Pharmaceuticals. The data presented on this page does not represent the view of Alexza Pharmaceuticals and its employees or that of Zippia.
Alexza Pharmaceuticals may also be known as or be related to Alexza Pharmaceuticals, Alexza Pharmaceuticals Inc, Alexza Pharmaceuticals Inc. and Alexza Pharmaceuticals, Inc.